M. Schroff

发表

A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA.

T. Sauerbruch, C. Ziske, I. Schmidt-Wolf, 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

Combination of MIDGE-Th1 DNA vaccines with the cationic lipid SAINT-18: studies on formulation, biodistribution and vector clearance.

M. Schroff, M. Ruiters, C. Kleuss, 2014, Vaccine.

Distinct immunological activation profiles of dSLIM® and ProMune® depend on their different structural context

M. Schroff, B. Wittig, C. Kleuss, 2016, Immunity, inflammation and disease.

Genuine Immunomodulation With dSLIM

M. Schroff, B. Wittig, C. Kleuss, 2014, Molecular therapy. Nucleic acids.

Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist

M. Schroff, B. Wittig, Manuel Schmidt, 2016, Molecular therapy oncolytics.

Immunization of Cats against Feline Immunodeficiency Virus (FIV) Infection by Using Minimalistic Immunogenic Defined Gene Expression Vector Vaccines Expressing FIV gp140 Alone or with Feline Interleukin-12 (IL-12), IL-16, or a CpG Motif

N. Pedersen, J. N. Flynn, C. Junghans, 2000, Journal of Virology.

Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study.

D. Schadendorf, M. Schroff, B. Wittig, 1998, British Journal of Cancer.

Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours.

M. Scheulen, H. Richly, A. Shimabukuro-Vornhagen, 2015, European journal of cancer.

Up-regulation by feline interleukin-4 and down-regulation by feline interferon-gamma of major histocompatibility complex class II on cat B-lymphocytes.

R. Nuñez, M. Schroff, B. Willett, 2002, Veterinary immunology and immunopathology.

Priming of immune responses to hepatitis B surface antigen with minimal DNA expression constructs modified with a nuclear localization signal peptide

J. Reimann, C. Junghans, M. Schroff, 2001, Journal of Molecular Medicine.

Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression

J. N. Flynn, C. Junghans, M. Schroff, 2000, AIDS.

Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703

M. Schroff, S. A. König-Merediz, B. Wittig, 2015, Nucleic acid therapeutics.

Specificity of the Receptor-G-Protein Interaction: Assigning Functions TO G-Protein Subunits by the Antisense Technique

G. Schultz, F. Kalkbrenner, M. Schroff, 1997 .

DNA immunisation with minimalistic expression constructs.

C. Junghans, M. Schroff, B. Wittig, 2004, Vaccine.

Immune response induced by a linear DNA vector: influence of dose, formulation and route of injection.

M. Schroff, B. Wittig, C. Kleuss, 2010, Vaccine.

Cationic Lipid-Formulated DNA Vaccine against Hepatitis B Virus: Immunogenicity of MIDGE-Th1 Vectors Encoding Small and Large Surface Antigen in Comparison to a Licensed Protein Vaccine

M. Schroff, M. Ruiters, C. Kleuss, 2014, PloS one.

Peripheral non-viral MIDGE vector-driven delivery of β-endorphin in inflammatory pain

M. Schroff, B. Wittig, H. Rittner, 2009, Molecular pain.

Ballistic CTLA4 and IL-4 gene transfer into the lower lid prolongs orthotopic corneal graft survival in mice

C. Junghans, M. Schroff, B. Wittig, 2003, Graefe's Archive for Clinical and Experimental Ophthalmology.

Influence of ballistic gene transfer on antigen-presenting cells in murine corneas

M. Schroff, B. Wittig, F. Hoffmann, 2002, Graefe's Archive for Clinical and Experimental Ophthalmology.

Transplantation of DBA/2 Mouse Corneas in BALB/c Recipients SignificantlyDelays Graft Rejection Compared with C3H Grafts and FacilitatesStudies on Gene Transfer

M. Schroff, B. Wittig, F. Hoffmann, 2008 .

Modular Multiantigen T Cell Epitope–Enriched DNA Vaccine Against Human Leishmaniasis

S. Croft, F. Modabber, C. Jaffe, 2014, Science Translational Medicine.

Cavrotolimod, a Nanoparticle Toll-like Receptor 9 Agonist, Inhibits Tumor Growth and Alters Immune Cell Composition in Mouse Models of Skin Cancer

M. Schroff, Weston L. Daniel, Scott Mix, 2023, ACS Applied Nano Materials.

IMPACT study: A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcincoma.

J. Trojan, M. Schroff, B. Wittig, 2012, Journal of Clinical Oncology.

Preliminary results of an ongoing phase II/III clinical study of the TLR9 agonist MGN1703 in patients with advanced colorectal carcinoma with disease control after first-line induction therapy (IMPACT Study).

W. Scheithauer, F. Mayer, M. Schroff, 2011, Journal of Clinical Oncology.

Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine

S. Croft, M. Schroff, K. Seifert, 2015, Gene Therapy.

Minimal size MIDGE vectors improve transgene expression in vivo.

T. Sauerbruch, C. Ziske, I. Schmidt-Wolf, 2007, In vivo.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Brief Communication: Stability and Catalytic Activity of Novel Circular DNAzymes

Georg Seifert, Burghardt Wittig, Karl Seeger, 2006, Nucleosides, nucleotides & nucleic acids.

Nuclear application of antisense oligonucleotides by microinjection and ballistomagnetic transfer to identify G protein heterotrimers activating phospholipase C.

G. Schultz, F. Kalkbrenner, M. Schroff, 1997, Methods in molecular biology.

Harnessing the Therapeutic Potential of Dendritic Cells

Manuel Schmidt, Matthias Schroff, Burghardt Wittig, 2020, Second Generation Cell and Gene-based Therapies.